Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease

This study has been completed.
Sponsor:
Information provided by:
Janssen-Cilag S.p.A.
ClinicalTrials.gov Identifier:
NCT00216502
First received: September 13, 2005
Last updated: January 20, 2011
Last verified: January 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: November 2005
  Estimated Primary Completion Date: No date given